• Aclarion announced the availability of a CEO shareholder letter covering the first half of 2026: CEO Shareholder Letter.
• Letter cited 141% year-over-year scan volume growth, 71% sequential growth, expanding Nociscan use in the U.S. and U.K.
• Highlighted U.K. reimbursement momentum, including coverage by Vitality, AXA, Aviva.
• Outlined U.S. market access push via PRIA Healthcare partnership, progress toward the CLARITY trial readout.
• Reported $16.3 million cash, no debt as of June 30, 2026, cash runway into the second half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.